Adenosine A 2A antagonists: potential preventive and palliative treatment for Parkinson's disease

Author： Morelli M.  

Publisher： Elsevier

ISSN： 0014-4886

Source： Experimental Neurology, Vol.184, Iss.1, 2003-11, pp. : 20-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The potential of GDNF as a treatment for Parkinson's disease

By Hurelbrink C.B.   Barker R.A.  

Experimental Neurology, Vol. 185, Iss. 1, 2004-01 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson's Disease

By Gołembiowska Krystyna  

Neurotoxicity Research, Vol. 24, Iss. 1, 2013-07 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite

Preladenant: an adenosine A2A receptor antagonist for Parkinson’s disease

By Zúñiga-Ramírez Carlos   Micheli Federico  

Future Neurology, Vol. 8, Iss. 6, 2013-11 ,pp. : 639-648

Future Medicine

Access to resources Recommend Favorite

Increased adenosine A 2A receptors in the brain of Parkinson’s disease patients with dyskinesias

By Calon Frédéric  

Brain, Vol. 127, Iss. 5, 2004-05 ,pp. : 1075-1084

Oxford University Press

Access to resources Recommend Favorite

N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease

By  

Current Alzheimer Research, Vol. 9, Iss. 6, 2012-07 ,pp. : 746-758

Bentham Science Publishers

Access to resources Recommend Favorite